Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial.

Ther Adv Gastroenterol · 2026 · PMC12891412 · PMID 41684726

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although there was a numerical superiority for the combination treatment, in terms of efficacy endpoints, the differences between the combination therapy and the monotherapy groups did not reach statistical significance for guselkumab, but did reach statistical significance for golimumab.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.